Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management

2021 ◽  
Vol 66 ◽  
pp. 92-100
Author(s):  
Larry R. Jackson ◽  
Kevin P. Jackson ◽  
Kevin L. Thomas
2018 ◽  
Vol 93 (5) ◽  
pp. 630-638 ◽  
Author(s):  
Sidakpal S. Panaich ◽  
Thomas Munger ◽  
Paul Friedman ◽  
Charanjit S. Rihal ◽  
David R. Holmes

2018 ◽  
Vol 4 (2) ◽  
pp. 53
Author(s):  
Harry J Crijns ◽  
Stefan G Spitzer ◽  
Claudio Tondo ◽  
◽  
◽  
...  

The left atrial appendage (LAA) is a key source of thrombi in patients with non-valvular atrial fibrillation (AF) and a major clinical focus for stroke prevention. Current surgical exclusion remains suboptimal and percutaneous approaches targeting the LAA, although well validated, fail to offer complete and durable occlusion for all patients. The high anatomical variability of the LAA demands a more tailored and targeted treatment approach. Epicardial LAA clip occlusion represents an important alternative approach for patients with AF not amenable to catheter closure or where anticoagulation is contraindicated. In this article, we briefly review the clinical evidence for epicardial devices in LAA occlusion, with a focus on the AtriClip and discuss their role in stroke prevention strategies.


2014 ◽  
Vol 62 (S 01) ◽  
Author(s):  
W. Reents ◽  
A. Diegeler ◽  
J. Babin-Ebell ◽  
A. Böning ◽  
R.P. Whitlock

2020 ◽  
Vol 12 (1) ◽  
pp. xiii
Author(s):  
Ranjan K. Thakur ◽  
Andrea Natale

BMJ Open ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. e044695
Author(s):  
Mu Chen ◽  
Qunshan Wang ◽  
Jian Sun ◽  
Peng-Pai Zhang ◽  
Wei Li ◽  
...  

IntroductionIt is the common clinical practice to prescribe indefinite aspirin for patients with non-valvular atrial fibrillation (NVAF) post left atrial appendage occlusion (LAAO). However, aspirin as a primary prevention strategy for cardiovascular diseases has recently been challenged due to increased risk of bleeding. Therefore, aspirin discontinuation after LAAO in atrial fibrillation (ASPIRIN LAAO) trial is designed to assess the uncertainty about the risks and benefits of discontinuing aspirin therapy at 6 months postimplantation with a Watchman LAAO device in NVAF patients.Methods and analysisThe ASPIRIN LAAO study is a prospective, multicentre, randomised, double-blinded, placebo-controlled non-inferiority trial. Patients implanted with a Watchman device within 6 months prior to enrollment and without pre-existing conditions requiring long-term aspirin therapy according to current guidelines are eligible for participating the trial. Subjects will be randomised in a 1:1 allocation ratio to either the Aspirin group (aspirin 100 mg/day) or the control group (placebo) at 6 months postimplantation. A total of 1120 subjects will be enrolled from 12 investigational sites in China. The primary composite endpoint is stroke, systemic embolism, cardiovascular/unexplained death, major bleeding, acute coronary syndrome and coronary or periphery artery disease requiring revascularisation at 24 months. Follow-up visits are scheduled at 6 and 12 months and then every 12 months until 24 months after the last patient recruitment.Ethics and disseminationEthics approval was obtained from the Ethics Committee of Xinhua Hospital, Shanghai, China (reference number XHEC-C-2018-065-5). The protocol is also submitted and approved by the institutional Ethics Committee at each participating centre. Results are expected in 2024 and will be disseminated through peer-reviewed journals and presentations at national and international conferences.Trial registration numberNCT03821883.


2021 ◽  
Vol 14 (16) ◽  
pp. 1852-1853
Author(s):  
Mahdi Veillet-Chowdhury ◽  
Stewart M. Benton ◽  
C. Anwar A. Chahal ◽  
James E. Harvey ◽  
Paul Tolerico ◽  
...  

2018 ◽  
Vol 71 (9) ◽  
pp. 755-756 ◽  
Author(s):  
Ignacio Cruz-González ◽  
Xavier Freixa ◽  
José Antonio Fernández-Díaz ◽  
José Carlos Moreno-Samos ◽  
Victoria Martín-Yuste ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document